These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34745932)

  • 1. Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis.
    Sun YM; Li W; Chen ZY; Wang Y
    Front Oncol; 2021; 11():651553. PubMed ID: 34745932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
    Chen X; Zhang Z; Hou X; Zhang Y; Zhou T; Liu J; Lin Z; Fang W; Yang Y; Ma Y; Huang Y; Zhao H; Zhang L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs).
    Long YX; Sun Y; Liu RZ; Zhang MY; Zhao J; Wang YQ; Zhou YW; Cheng K; Chen Y; Zhu CR; Liu JY
    Curr Oncol; 2022 Jan; 29(1):267-282. PubMed ID: 35049699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
    Fujiwara Y; Horita N; Namkoong H; Galsky MD
    Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

  • 9. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
    Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
    EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
    Hong B; Du B; Chen R; Zheng C; Ni R; Liu M; Yang J
    BMC Med; 2024 Feb; 22(1):75. PubMed ID: 38373990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.
    Liu K; Qin Z; Xu X; Li T; Ge Y; Mao H; Xing C
    Front Oncol; 2021; 11():662731. PubMed ID: 34221977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.
    Ma K; Lu Y; Jiang S; Tang J; Li X; Zhang Y
    Front Pharmacol; 2018; 9():1430. PubMed ID: 30618738
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
    Zheng J; Huang B; Xiao L; Wu M; Li J
    Front Oncol; 2022; 12():821626. PubMed ID: 36568203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
    Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
    JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Da L; Teng Y; Wang N; Zaguirre K; Liu Y; Qi Y; Song F
    Front Pharmacol; 2019; 10():1671. PubMed ID: 32082164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis.
    Wei W; Ding Y; He J; Wu J
    Transl Cancer Res; 2020 Jul; 9(7):4173-4187. PubMed ID: 35117786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review¬†and network meta-analysis.
    Huang Y; Fan H; Li N; Du J
    Cancer Med; 2019 May; 8(5):2664-2674. PubMed ID: 30950194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
    Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.